Uptake of 18F-labeled anti-PD-L1 adnectin (18F-BMS-986192) and 89Zr-nivolumab in patients with NSCLC was correlated with PD-(L)1 expression by immunohistochemistry in tumor tissues [100]. This evidence concerns the gene CD274 and neoplasm.